Identification

Name
Felbamate
Accession Number
DB00949  (APRD00505)
Type
Small Molecule
Groups
Approved
Description

Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.

Structure
Thumb
Synonyms
  • 2-Phenyl-1,3-propanediol dicarbamate
  • Carbamic acid 2-phenyltrimethylene ester
  • Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester
  • Felbamate
  • Felbamato
  • Felbamatum
External IDs
ADD-03055 / W-554
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FelbamateTablet400 mg/1OralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs
FelbamateTablet600 mg/1OralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs
FelbamateSuspension600 mg/5mLOralWallace Pharmaceuticals Inc.2011-11-23Not applicableUs
FelbatolTablet400 mg/1OralMeda Pharmaceuticals Ltd1993-07-29Not applicableUs
FelbatolTablet600 mg/1OralMeda Pharmaceuticals Ltd1993-07-29Not applicableUs
FelbatolSuspension600 mg/5mLOralMeda Pharmaceuticals Ltd1993-07-29Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FelbamateTablet600 mg/1OralCadila Pharnmaceuticals2017-08-15Not applicableUs
FelbamateTablet600 mg/1OralImpax Generics2017-03-06Not applicableUs
FelbamateTablet600 mg/1OralCarilion Materials Management2011-09-16Not applicableUs
FelbamateSuspension600 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2017-06-16Not applicableUs
FelbamateSuspension600 mg/5mLOralAmneal Pharmaceuticals2011-12-16Not applicableUs
FelbamateTablet400 mg/1OralCadila Pharnmaceuticals2017-08-15Not applicableUs
FelbamateTablet400 mg/1OralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs
FelbamateTablet600 mg/1OralMylan Pharmaceuticals2016-01-122018-03-31Us
FelbamateTablet400 mg/1OralAlvogen, Inc.2016-12-28Not applicableUs
FelbamateTablet400 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-15Not applicableUs
International/Other Brands
Felbamyl / Taloxa
Categories
UNII
X72RBB02N8
CAS number
25451-15-4
Weight
Average: 238.2399
Monoisotopic: 238.095356946
Chemical Formula
C11H14N2O4
InChI Key
WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
IUPAC Name
3-(carbamoyloxy)-2-phenylpropyl carbamate
SMILES
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1

Pharmacology

Indication

For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.

Structured Indications
Pharmacodynamics

Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex.

Mechanism of action

The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.

TargetActionsOrganism
AGlutamate receptor ionotropic, NMDA 2B
antagonist
Human
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
AGlutamate receptor ionotropic, NMDA 2A
antagonist
Human
Absorption

>90%

Volume of distribution
  • 756±82 mL/kg
Protein binding

20-36%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

20-23 hours

Clearance
  • 26 +/- 3 mL/hr/kg [single 1200 mg dose]
  • 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
Toxicity

LD50=5000 mg/kg (Orally in rats)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Felbamate Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Felbamate.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Felbamate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Felbamate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Felbamate.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Felbamate.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Felbamate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Felbamate.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Felbamate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Felbamate.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Felbamate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Felbamate.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Felbamate.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Felbamate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Felbamate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Felbamate.Approved
AmobarbitalThe serum concentration of Amobarbital can be increased when it is combined with Felbamate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Felbamate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Felbamate.Experimental
AnagrelideFelbamate may increase the QTc-prolonging activities of Anagrelide.Approved
AprepitantThe serum concentration of Felbamate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.Approved, Investigational
Arsenic trioxideFelbamate may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherFelbamate may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Felbamate.Approved
AsenapineFelbamate may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Felbamate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Felbamate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Felbamate.Investigational, Vet Approved
AzelastineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinFelbamate may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Felbamate.Approved
BarbexacloneThe serum concentration of Barbexaclone can be increased when it is combined with Felbamate.Experimental
BarbitalThe serum concentration of Barbital can be increased when it is combined with Felbamate.Illicit
BedaquilineFelbamate may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Felbamate.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Felbamate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Felbamate.Approved
BoceprevirThe metabolism of Felbamate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Felbamate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Felbamate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Felbamate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Felbamate.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Felbamate.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Felbamate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Felbamate.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felbamate.Approved, Investigational
BuprenorphineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Felbamate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Felbamate.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Felbamate.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Felbamate.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Felbamate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Felbamate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Felbamate.Investigational
CarbamazepineThe serum concentration of Felbamate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Felbamate.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Felbamate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate.Approved
CeritinibThe serum concentration of Felbamate can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Felbamate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Felbamate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Felbamate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Felbamate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Felbamate.Approved
ChloroquineFelbamate may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Felbamate.Investigational, Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Felbamate is combined with Chlorphenamine.Approved
ChlorpromazineFelbamate may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Felbamate.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Felbamate.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Felbamate.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Felbamate.Approved, Vet Approved
CiprofloxacinFelbamate may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideFelbamate may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramFelbamate may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Felbamate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Felbamate can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Felbamate.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Felbamate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Felbamate.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Felbamate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Felbamate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Felbamate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Felbamate.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Felbamate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Felbamate.Experimental
ClotrimazoleThe metabolism of Felbamate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineFelbamate may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Felbamate can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Felbamate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Felbamate.Approved, Illicit
ConivaptanThe serum concentration of Felbamate can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Felbamate.Approved
CrizotinibFelbamate may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.Approved
CyclosporineThe metabolism of Felbamate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Felbamate.Approved
Cyproterone acetateThe serum concentration of Felbamate can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Felbamate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Felbamate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Felbamate can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Felbamate.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Felbamate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Felbamate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Felbamate.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Felbamate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Felbamate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felbamate.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Felbamate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Felbamate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Felbamate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Felbamate.Approved, Illicit, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Felbamate.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Felbamate.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Felbamate.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Felbamate.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Felbamate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Felbamate.Approved, Illicit
DihydroergotamineThe metabolism of Felbamate can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Felbamate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Felbamate.Experimental, Illicit
DiltiazemThe metabolism of Felbamate can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Felbamate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Felbamate.Approved, Illicit
DisopyramideFelbamate may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Felbamate.Experimental
DofetilideFelbamate may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronFelbamate may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneFelbamate may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Felbamate.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Felbamate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Felbamate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Felbamate.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Illicit
DronedaroneFelbamate may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Felbamate.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Felbamate.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Felbamate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Felbamate.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Felbamate.Approved, Investigational
EliglustatFelbamate may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Felbamate.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Felbamate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Felbamate.Approved, Investigational
EnzalutamideThe serum concentration of Felbamate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinFelbamate may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramFelbamate may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Felbamate.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Felbamate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Felbamate.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Felbamate.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Felbamate.Approved
EthanolFelbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Felbamate.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Felbamate.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Felbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Felbamate.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Felbamate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Felbamate.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Felbamate.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Felbamate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Felbamate.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Felbamate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Felbamate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Felbamate.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Felbamate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Felbamate is combined with Ezogabine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Felbamate.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Felbamate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Felbamate is combined with Fexofenadine.Approved
FlecainideFelbamate may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Felbamate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Felbamate.Experimental
FluconazoleThe metabolism of Felbamate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Felbamate.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Felbamate.Approved, Illicit
FluoxetineFelbamate may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolFelbamate may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Felbamate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Felbamate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Felbamate.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Felbamate.Approved
FluvoxamineThe metabolism of Felbamate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Felbamate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Felbamate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Felbamate can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Felbamate.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Felbamate can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Felbamate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Felbamate is combined with Gabapentin Enacarbil.Approved
Gadobenic acidFelbamate may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Felbamate.Approved, Illicit, Investigational
GemifloxacinFelbamate may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Felbamate.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Felbamate.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Felbamate.Approved, Illicit
GoserelinFelbamate may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronFelbamate may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Felbamate.Approved, Illicit, Withdrawn
HaloperidolFelbamate may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Felbamate.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Felbamate.Approved, Illicit, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Felbamate.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Felbamate.Approved
HydrocodoneFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
IbutilideFelbamate may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Felbamate can be increased when it is combined with Idelalisib.Approved
IloperidoneFelbamate may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Felbamate can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Felbamate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Felbamate can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Felbamate.Investigational
IsavuconazoniumThe metabolism of Felbamate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Felbamate.Approved, Vet Approved
IsoniazidThe metabolism of Felbamate can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Felbamate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Felbamate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Felbamate can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Felbamate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Felbamate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Felbamate.Approved, Investigational
KetoconazoleThe metabolism of Felbamate can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate.Approved, Investigational
LenvatinibFelbamate may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideFelbamate may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Felbamate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felbamate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Felbamate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Felbamate is combined with Levodopa.Approved
LevofloxacinFelbamate may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Felbamate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Felbamate is combined with Levomilnacipran.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Felbamate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Felbamate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Felbamate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Felbamate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Felbamate.Illicit
LopinavirThe metabolism of Felbamate can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Felbamate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Felbamate.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Felbamate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Felbamate.Approved
LovastatinThe metabolism of Felbamate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Felbamate.Approved
LuliconazoleThe serum concentration of Felbamate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Felbamate can be increased when combined with Lumacaftor.Approved
LumefantrineFelbamate may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Felbamate.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Felbamate.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Felbamate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Felbamate.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Felbamate.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Felbamate.Approved, Investigational
MefloquineThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Felbamate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Felbamate.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Felbamate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Felbamate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Felbamate.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Felbamate.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.Approved
MethadoneFelbamate may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Felbamate.Approved, Illicit
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Felbamate.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Felbamate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Felbamate.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.Approved, Vet Approved
MethohexitalThe serum concentration of Methohexital can be increased when it is combined with Felbamate.Approved
MethotrimeprazineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Felbamate.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Felbamate.Experimental
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be increased when it is combined with Felbamate.Approved
MetyrosineFelbamate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Felbamate.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Felbamate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Investigational
MirtazapineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Felbamate can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Felbamate.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Felbamate.Approved, Investigational
MoxifloxacinFelbamate may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Felbamate.Approved
NefazodoneThe metabolism of Felbamate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Felbamate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Felbamate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Felbamate can be increased when combined with Nevirapine.Approved
NicotineThe metabolism of Felbamate can be decreased when combined with Nicotine.Approved
NilotinibFelbamate may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Felbamate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Felbamate.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Felbamate.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Felbamate.Investigational
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Felbamate.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Felbamate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Felbamate.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Felbamate.Approved
OfloxacinFelbamate may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Felbamate.Approved, Investigational
OlaparibThe metabolism of Felbamate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbamate.Approved
OndansetronFelbamate may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Felbamate.Approved, Illicit
OrlistatThe serum concentration of Felbamate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Felbamate.Investigational
OsimertinibThe serum concentration of Felbamate can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Felbamate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Felbamate.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Felbamate.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Felbamate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Felbamate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Felbamate.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.Approved
PaliperidoneFelbamate may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatFelbamate may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeFelbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.Approved, Investigational
PazopanibFelbamate may increase the QTc-prolonging activities of Pazopanib.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Felbamate.Experimental
PentamidineFelbamate may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.Approved, Vet Approved
PentobarbitalThe serum concentration of Pentobarbital can be increased when it is combined with Felbamate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Felbamate.Investigational
PerflutrenFelbamate may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Felbamate.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Felbamate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Felbamate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Felbamate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Felbamate.Experimental
PhenobarbitalThe serum concentration of Felbamate can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Felbamate.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Felbamate.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Felbamate.Approved, Vet Approved
PimozideFelbamate may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felbamate.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Felbamate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Felbamate.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Felbamate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Felbamate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleFelbamate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Felbamate.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Felbamate.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Felbamate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Felbamate.Approved
PrimaquineFelbamate may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Felbamate.Approved, Vet Approved
ProcainamideFelbamate may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Felbamate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.Approved, Vet Approved
PromazineFelbamate may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Felbamate is combined with Promethazine.Approved
PropafenoneFelbamate may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Felbamate.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Felbamate.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Felbamate.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Felbamate.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Felbamate.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Felbamate.Approved, Illicit
QuetiapineFelbamate may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineFelbamate may increase the QTc-prolonging activities of Quinidine.Approved
QuinineFelbamate may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Felbamate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Felbamate.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Felbamate can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felbamate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Felbamate.Approved, Investigational
RifabutinThe metabolism of Felbamate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Felbamate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Felbamate can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Felbamate.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Felbamate.Vet Approved
RopiniroleFelbamate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate.Approved
RotigotineFelbamate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Felbamate.Approved
SaquinavirThe metabolism of Felbamate can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Felbamate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.Approved
SecobarbitalThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Felbamate.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Felbamate.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felbamate.Approved, Vet Approved
SildenafilThe metabolism of Felbamate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Felbamate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Felbamate can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
SotalolFelbamate may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Felbamate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Felbamate can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.Approved, Investigational
SulfisoxazoleFelbamate may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Felbamate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Felbamate.Experimental
SuvorexantFelbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Felbamate.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Felbamate.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Felbamate is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Felbamate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinFelbamate may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Felbamate can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Felbamate.Approved
TetrabenazineFelbamate may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Felbamate.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Felbamate.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Felbamate.Investigational
ThalidomideFelbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Felbamate.Approved, Vet Approved
ThiopentalThe serum concentration of Thiopental can be increased when it is combined with Felbamate.Approved, Vet Approved
ThioridazineFelbamate may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Felbamate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Felbamate.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Felbamate.Approved, Investigational
TiclopidineThe metabolism of Felbamate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Felbamate.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Felbamate.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.Approved
TocilizumabThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felbamate.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate.Approved
ToremifeneFelbamate may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Felbamate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Felbamate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Felbamate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Felbamate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Felbamate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Felbamate.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Felbamate.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Felbamate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Felbamate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Felbamate.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Felbamate.Approved
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Felbamate.Approved, Investigational
VandetanibFelbamate may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibFelbamate may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Felbamate can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Felbamate.Experimental
VerapamilThe metabolism of Felbamate can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Felbamate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Felbamate.Experimental
VoriconazoleThe metabolism of Felbamate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Felbamate.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Felbamate.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Felbamate.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Felbamate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Felbamate is combined with Zimelidine.Withdrawn
ZiprasidoneFelbamate may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Felbamate.Vet Approved
ZolpidemFelbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Felbamate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Felbamate.Approved, Investigational
ZuclopenthixolFelbamate may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Taking it after a meal may reduce the incidence of adverse effects.

References

General References
  1. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991 Nov;41(11):1785-9. [PubMed:1944909]
External Links
Human Metabolome Database
HMDB15084
KEGG Drug
D00536
KEGG Compound
C07501
PubChem Compound
3331
PubChem Substance
46506375
ChemSpider
3214
BindingDB
50088430
ChEBI
4995
ChEMBL
CHEMBL1094
Therapeutic Targets Database
DAP000093
PharmGKB
PA449590
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Felbamate
ATC Codes
N03AX10 — Felbamate
MSDS
Download (47.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SuspensionOral600 mg/5mL
TabletOral400 mg/1
TabletOral600 mg/1
Prices
Unit descriptionCostUnit
Felbatol 600 mg tablet3.1USD tablet
Felbatol 400 mg tablet2.71USD tablet
Felbatol 600 mg/5ml Suspension1.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4978680No1992-09-262009-09-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)151.5 °CPhysProp
water solubilitySlightly soluble in waterNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.742 mg/mLALOGPS
logP0.56ALOGPS
logP0.68ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.59 m3·mol-1ChemAxon
Polarizability23.52 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9544
Blood Brain Barrier+0.9805
Caco-2 permeable-0.6324
P-glycoprotein substrateNon-substrate0.783
P-glycoprotein inhibitor INon-inhibitor0.9551
P-glycoprotein inhibitor IINon-inhibitor0.932
Renal organic cation transporterNon-inhibitor0.9039
CYP450 2C9 substrateNon-substrate0.9009
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7942
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9184
CYP450 2D6 inhibitorInhibitor0.7126
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9271
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.8338
BiodegradationNot ready biodegradable0.8068
Rat acute toxicity1.7095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9872
hERG inhibition (predictor II)Non-inhibitor0.9786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-5900000000-673caaab3dded596924c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2900000000-880b1fb1822a512a352c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-016r-1900000000-f04127a0f39b9e0b001f

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Carbamate esters / Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Monocyclic benzene moiety / Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carbamate ester (CHEBI:4995)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic site...
Gene Name
GRIN2B
Uniprot ID
Q13224
Uniprot Name
Glutamate receptor ionotropic, NMDA 2B
Molecular Weight
166365.885 Da
References
  1. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD: Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther. 1999 May;289(2):886-94. [PubMed:10215667]
  2. Harty TP, Rogawski MA: Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000 Mar;39(1):47-55. [PubMed:10690753]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Chang HR, Kuo CC: Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. doi: 10.1021/jm0706618. Epub 2008 Feb 27. [PubMed:18311896]
  5. Luszczki JJ, Danysz W, Czuczwar SJ: Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. doi: 10.1159/000114870. Epub 2008 Feb 4. [PubMed:18253065]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of sub...
Gene Name
GRIN2A
Uniprot ID
Q12879
Uniprot Name
Glutamate receptor ionotropic, NMDA 2A
Molecular Weight
165281.215 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Foye, William O.;Williams, David A.;Lemke, Thomas L. (2002). Foye's Principles of Medicinal Chemistry (5th ed.). Lippincott Williams & Wilkins. [ISBN:0683307371]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:44